These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 37735428

  • 1. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
    Marfo K, Dei-Adomakoh Y, Segbefia C, Dwomoh D, Edgal A, Ampah N, Ramachandrachar BC, Subramanyam K, Natarajan A, Egbujo O, Ataga KI.
    BMC Health Serv Res; 2023 Sep 21; 23(1):1018. PubMed ID: 37735428
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, Yuce H.
    Health Qual Life Outcomes; 2019 Oct 16; 17(1):155. PubMed ID: 31619251
    [Abstract] [Full Text] [Related]

  • 7. Sickle cell disease complications: Prevalence and resource utilization.
    Shah N, Bhor M, Xie L, Paulose J, Yuce H.
    PLoS One; 2019 Oct 16; 14(7):e0214355. PubMed ID: 31276525
    [Abstract] [Full Text] [Related]

  • 8. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A, Cong Z, Agodoa I, Song X, Martinez DJ, Black D, Lew CR, Varker H, Chan C, Lanzkron S.
    J Manag Care Spec Pharm; 2020 Sep 16; 26(9):1121-1129. PubMed ID: 32597290
    [Abstract] [Full Text] [Related]

  • 9. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
    Kang HA, Barner JC, Lawson KA, Rascati K, Mignacca RC.
    Am J Hematol; 2023 Jan 16; 98(1):90-101. PubMed ID: 36251408
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
    Lobo C, Moura P, Fidlarczyk D, Duran J, Barbosa R, Oliveira T, do Nascimento EM, Bhakta N, Hankins JS.
    BMC Health Serv Res; 2022 Jan 08; 22(1):42. PubMed ID: 34998394
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA, Barner JC, Richards KM, Bhor M, Paulose J, Kutlar A.
    J Health Econ Outcomes Res; 2020 Jan 08; 7(1):94-101. PubMed ID: 32685602
    [Abstract] [Full Text] [Related]

  • 14. Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort.
    Strunk C, Tartaglione I, Piccone CM, Colombatti R, Andemariam B, Manwani D, Smith A, Haile H, Kim E, Wilson S, Asare EV, Rivers A, Farooq F, Urbonya R, Boruchov D, Boatemaa GD, Perrotta S, Ekem I, Sainati L, Rao S, Zempsky W, Sey F, Antwi-Boasiako C, Segbefia C, Inusa B, Campbell AD.
    Blood Cells Mol Dis; 2021 Dec 08; 92():102612. PubMed ID: 34564050
    [Abstract] [Full Text] [Related]

  • 15. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
    Kang HA, Barner JC, Richards KM, Bhor M, Paulose J, Kutlar A.
    J Health Econ Outcomes Res; 2020 Dec 08; 7(1):94-101. PubMed ID: 36873574
    [Abstract] [Full Text] [Related]

  • 16. Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
    Beillat M, Durand-Zaleski I, Pirenne F, Bénard S, Chillotti L, Galacteros F.
    Front Public Health; 2023 Dec 08; 11():1215605. PubMed ID: 37808997
    [Abstract] [Full Text] [Related]

  • 17. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes.
    Bou-Maroun LM, Meta F, Hanba CJ, Campbell AD, Yanik GA.
    Pediatr Blood Cancer; 2018 Jan 08; 65(1):. PubMed ID: 28801954
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
    Gallagher ME, Chawla A, Brady BL, Badawy SM.
    J Med Econ; 2022 Jan 08; 25(1):1140-1148. PubMed ID: 36222016
    [Abstract] [Full Text] [Related]

  • 19. Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?
    Hegemann L, Narasimhan V, Marfo K, Kuma-Aboagye P, Ofori-Acquah S, Odame I.
    Ann Glob Health; 2023 Jan 08; 89(1):76. PubMed ID: 38025926
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
    Desai RJ, Mahesri M, Globe D, Mutebi A, Bohn R, Achebe M, Levin R, Schneeweiss S.
    Ann Hematol; 2020 Nov 08; 99(11):2497-2505. PubMed ID: 32869184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.